Navamedic ASA (OSL:NAVA)

Market Cap	503.61M +14.0%
Revenue (ttm)	565.36M +6.4%
Net Income	-23.54M
EPS	n/a
Shares Out	23.98M
PE Ratio	n/a
Forward PE	50.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,003
Average Volume	9,590
Open	21.30
Previous Close	21.00
Day's Range	20.60 - 21.30
52-Week Range	17.10 - 27.90
Beta	0.17
RSI	36.73
Earnings Date	Feb 12, 2026

About Navamedic ASA

Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. The company’s product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic and propioni...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 2002
• Employees: 42
• Stock Exchange: Oslo Børs
• Ticker Symbol: NAVA

Financial Performance

In 2025, Navamedic ASA's revenue was 565.36 million, an increase of 6.38% compared to the previous year's 531.44 million. Losses were -23.54 million, 329.1% more than in 2024.